液相色谱串联质谱法分析人体内儿茶酚胺及其代谢产物的研究进展
Research Progress in the Analysis of Catecholamines and Their Metabolites in Human Body by Liquid Chromatography Tandem Mass Spectrometry
摘要: 儿茶酚胺,包括肾上腺素、去甲肾上腺素和多巴胺,是由酪氨酸在一系列酶的催化作用下合成的。儿茶酚胺通过自主调节在生理活动中发挥重要作用,维持人体的动态平衡。儿茶酚胺及其代谢物的异常浓度(特别是高浓度)常提示神经内分泌肿瘤,特别是嗜铬细胞瘤和副神经节瘤的发生。嗜铬细胞瘤和副神经节瘤的显著特点是不规律地释放儿茶酚胺,有时呈爆炸式释放,以及顽固性高血压。正是由于这些性质,嗜铬细胞瘤和副神经节瘤可出现许多严重的并发症,但目前对嗜铬细胞瘤和副神经节瘤的诊断率很低。原因之一是其临床表现具有高度的异质性和多样性,但更重要的原因是缺乏一种筛选和诊断嗜铬细胞瘤和副神经节瘤的超敏方法。目前,医学组织通常通过检测尿液或血浆中的儿茶酚胺来筛查嗜铬细胞瘤和副神经节瘤。然而,儿茶酚胺及其某些代谢物的浓度低、不稳定、极性高、分子结构高度相似,使得儿茶酚胺的准确定量非常困难。本文概述了儿茶酚胺及其代谢物的检测现状,讨论了液相色谱串联质谱法联合检测儿茶酚胺及其代谢物的必要性,阐述了联合检测方法开发与验证的基本步骤及注意事项。
Abstract: Catecholamine, including epinephrine, norepinephrine and dopamine, is derived from tyrosine by the catalysis of a series of enzymes. Catecholamines take an important role in physiological activity via autonomic regulation and keep a dynamic balance in human body. The abnormal concentration (particularly the high level) of catecholamines and their metabolites often indicates the occurrence of neuron endocrine neoplasm especially pheochromocytoma and paraganglioma. The prominent features of pheochromocytoma and paraganglioma are releasing Catecholamines irregularly and sometimes explosively as well as refractory hypertension. It is because these nature, pheochromocytoma and paraganglioma can present with lots of serious complications. Unfortunately, the diagnosis rate of pheochromocytoma and paraganglioma is very low. One reason is its high heterogeneity and protean clinical presentation, but the more important reason is lacking a hypersensitive method to screen and diagnose pheochromocytoma and paraganglioma. At present, medical organization usually screens pheochromocytoma and paraganglioma by detecting the Catecholamines in urine or plasma. However, low concentration, instability, high polarity and high similarity in molecular structure of some metabolites make it very difficult for accurate quantification of the Catecholamines. In this paper, the detection status of catecholamine and its metabolites is summarized, the necessity of LC-MS/MS combined detection of catecholamine and its metabolites is discussed, and the basic steps and precautions of the development and verification of the combined detection method are explained.
文章引用:闫亚娟, 黄猛, 伦立民. 液相色谱串联质谱法分析人体内儿茶酚胺及其代谢产物的研究进展[J]. 临床医学进展, 2021, 11(4): 1571-1578. https://doi.org/10.12677/ACM.2021.114225

参考文献

[1] Eisenhofer, G., Huynh, T., Hiroi, M., et al. (2001) Understanding Catecholamine Metabolism as a Guide to the Biochemical Diagnosis of Pheochromocytoma. Reviews in Endocrine and Metabolic Disorders, 2, 297-311. [Google Scholar] [CrossRef
[2] Eisenhofer, G., Rundquist, B., Aneman, A., et al. (1995) Regional Release and Removal of Catecholamines and Extraneuronal Metabolism to Metanephrines. The Journal of Clinical Endocrinology and Metabolism, 80, 3009-3017. [Google Scholar] [CrossRef] [PubMed]
[3] Niwa, M., Matsumoto, Y., Mouri, A., et al. (2011) Vulnerability in Early Life to Changes in the Rearing Environment Plays a Crucial Role in the Aetiopathology of Psychiatric Disorders. The International Journal of Neuropsychopharmacology, 14, 459-477. [Google Scholar] [CrossRef
[4] Eisenhofer, G., Kopin, I.J. and Goldstein, D.S. (2004) Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine. Pharmacological Reviews, 56, 331-349. [Google Scholar] [CrossRef] [PubMed]
[5] Gu, Y.W., Poste, J., Kunal, M., et al. (2017) Cardiovascular Manifestations of Pheochromocytoma. Cardiology in Review, 25, 215-222. [Google Scholar] [CrossRef
[6] Prejbisz, A., Lenders, J.W.M., Eisenhofer, G., et al. (2013) Mortality Associated with Phaeochromocytoma. Hormone and Metabolic Research, 45, 154. [Google Scholar] [CrossRef] [PubMed]
[7] Stolk, R.F., Bakx, C., Mulder, J., et al. (2013) Is the Excess Cardiovascular Morbidity in Pheochromocytoma Related to Blood Pressure or to Catecholamines? The Journal of Clinical Endocrinology & Metabolism, 98, 1100-1106. [Google Scholar] [CrossRef] [PubMed]
[8] Lenders, J.W., Eisenhofer, G., Mannelli, M., et al. (2005) Phaeochromocytoma. The Lancet, 366, 665-675. [Google Scholar] [CrossRef
[9] Berends, A.M.A., Buitenwerf, E., de Krijger, R.R., et al. (2018) Incidence of Pheochromocytoma and Sympathetic Paraganglioma in the Netherlands: A Nationwide Study and Systematic Review. European Journal of Internal Medicine, 51, 68-73. [Google Scholar] [CrossRef] [PubMed]
[10] Zuber, S.M., Kantorovich, V. and Pacak, K. (2011) Hypertension in Pheochromocytoma: Characteristics and Treatment. Endocrinology and Metabolism Clinics of North America, 40, 295-311. [Google Scholar] [CrossRef] [PubMed]
[11] Manger, W.M. (2009) The Protean Manifestations of Pheochromocytoma. Hormone and Metabolic Research, 41, 658. [Google Scholar] [CrossRef] [PubMed]
[12] Li, X.S., Li, S. and Kellermann, G. (2016) Pre-Analytical and Analytical Validations and Clinical Applications of a Miniaturized, Simple and Cost-Effective Solid Phase Extraction Combined with LC-MS/MS for the Simultaneous Determination of Catecholamines and Metanephrines in Spot Urine Samples. Talanta, 159, 238-247. [Google Scholar] [CrossRef] [PubMed]
[13] Pussard, E., Chaouch, A. and Said, T. (2014) Radioimmunoassay of Free Plasma Metanephrines for the Diagnosis of Catecholamine-Producing Tumors. Clinical Chemistry and Laboratory Medicine, 52, 437-444. [Google Scholar] [CrossRef] [PubMed]
[14] Eisenhofer, G., Peitzsch, M. and Mcwhinney, B.C. (2016) Impact of LC-MS/MS on the Laboratory Diagnosis of Catecholamine-Producing Tumors. TrAC Trends in Analytical Chemistry, 84, 106-116. [Google Scholar] [CrossRef
[15] Davies, S.L. and Davison, A.S. (2019) Liquid Chromatography Tandem Mass Spectrometry for Plasma Metadrenalines. Clinica Chimica Acta, 495, 512-521. [Google Scholar] [CrossRef] [PubMed]
[16] Eisenhofer, G. and Peitzsch, M. (2014) Laboratory Evaluation of Pheochromocytoma and Paraganglioma. Clinical Chemistry, 60, 1486-1499. [Google Scholar] [CrossRef] [PubMed]
[17] Eisenhofer, G., Lenders, J.W.M., Siegert, G., et al. (2012) Plasma Methoxytyramine: A Novel Biomarker of Metastatic Pheochromocytoma and Paraganglioma in Relation to Established Risk Factors of Tumour Size, Location and SDHB Mutation Status. European Journal of Cancer, 48, 1739-1749. [Google Scholar] [CrossRef] [PubMed]
[18] Willemsen, J.J., Ross, H.A., Lenders, J.W., et al. (2007) Stability of Urinary Fractionated Metanephrines and Catecholamines during Collection, Shipment, and Storage of Samples. Clinical Chemistry, 53, 268-272. [Google Scholar] [CrossRef] [PubMed]
[19] Chen, H., Sippel, R.S., O’dorisio, M.S., et al. (2010) The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors. Pancreas, 39, 775-783. [Google Scholar] [CrossRef
[20] Berends, A., Eisenhofer, G., Fishbein, L., et al. (2019) Intricacies of the Molecular Machinery of Catecholamine Biosynthesis and Secretion by Chromaffin Cells of the Normal Adrenal Medulla and in Pheochromocytoma and Paraganglioma. Cancers (Basel), 11, 1121. [Google Scholar] [CrossRef] [PubMed]
[21] Grouzmann, E., Centeno, C. and Eugster, P.J. (2018) Quantification of Vanillylmandelic Acid, Homovanillic Acid and 5-Hydroxyindoleacetic Acid in Urine Using a Dilute-and-Shoot and Ultra-High Pressure Liquid Chromatography Tandem Mass Spectrometry Method. Clinical Chemistry and Laboratory Medicine (CCLM), 56, 1533-1541. [Google Scholar] [CrossRef] [PubMed]
[22] Eisenhofer, G., Prejbisz, A., Peitzsch, M., et al. (2018) Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. Clinical Chemistry, 64, 1646-1656. [Google Scholar] [CrossRef] [PubMed]
[23] Eisenhofer, G. and Lenders, J.W.M. (2018) Biochemical Diagnosis of Pheochromocytoma, a Rediscovered Catecholamine-Metabolizing Tumor. Clinical Chemistry, 64, 1780-1781. [Google Scholar] [CrossRef] [PubMed]
[24] Eisenhofer, G., Peitzsch, M., Kaden, D., et al. (2019) Reference Intervals for LC-MS/MS Measurements of Plasma Free, Urinary Free and Urinary Acid-Hydrolyzed Deconjugated Normetanephrine, Metanephrine and Methoxytyramine. Clinica Chimica Acta, 490, 46-54. [Google Scholar] [CrossRef] [PubMed]
[25] Verly, I.R., van Kuilenburg, A.B., Abeling, N.G.G.M., et al. (2017) Catecholamines Profiles at Diagnosis: Increased Diagnostic Sensitivity and Correlation with Biological and Clinical Features in Neuroblastoma Patients. European Journal of Cancer, 72, 235-243. [Google Scholar] [CrossRef] [PubMed]
[26] Verly, I.R.N., van Kuilenburg, A.B.P., Abeling, N.G.G.M., et al. (2018) 3-Methoxytyramine: An Independent Prognostic Biomarker That Associates with High-Risk Disease and Poor Clinical Outcome in Neuroblastoma Patients. European Journal of Cancer, 90, 102-110. [Google Scholar] [CrossRef] [PubMed]
[27] Patin, F., Crinière, L., Francia, T., et al. (2016) Low Specificity of Urinary 3-Methoxytyramine in Screening of Dopamine-Secreting Pheochromocytomas and Paragangliomas. Clinical Biochemistry, 49, 1205-1208. [Google Scholar] [CrossRef] [PubMed]
[28] Wang, J., Zhou, L., Lei, H., et al. (2017) Simultaneous Quantification of Amino Metabolites in Multiple Metabolic Pathways Using Ultra-High Performance Liquid Chromatography with Tandem-Mass Spectrometry. Scientific Reports, 7, 1416-1423. [Google Scholar] [CrossRef] [PubMed]
[29] Yu, S., Yin, Y., Li, Q., et al. (2019) Validation of an Improved Liquid Chromatography Tandem Mass Spectrometry Method for Rapid and Simultaneous Analysis of Plasma Catecholamine and Their Metabolites. Journal of Chromatography B, 1129, Article ID: 121805. [Google Scholar] [CrossRef] [PubMed]
[30] Verly, I.R., Van Kuilenburg, A.B., Abeling, N.G., et al. (2017) Catecholamines Profiles at Diagnosis: Increased Diagnostic Sensitivity and Correlation with Biological and Clinical Features in Neuroblastoma Patients. European Journal of Cancer, 72, 235-243. [Google Scholar] [CrossRef] [PubMed]
[31] Rao, J.U., Engelke, U.F.H., Rodenburg, R.J.T., et al. (2013) Genotype-Specific Abnormalities in Mitochondrial Function Associate with Distinct Profiles of Energy Metabolism and Catecholamine Content in Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 19, 3787-3795. [Google Scholar] [CrossRef
[32] Verly, I.R.N., Leen, R., Meinsma, J.R., et al. (2019) Catecholamine Excretion Profiles Identify Clinical Subgroups of Neuroblastoma Patients. European Journal of Cancer, 111, 21-29. [Google Scholar] [CrossRef] [PubMed]
[33] Mamilla, D., Gonzales, M.K., Esler, M.D., et al. (2019) Pseudopheochromocytoma. Endocrinology and Metabolism Clinics of North America, 48, 751-764. [Google Scholar] [CrossRef] [PubMed]
[34] Rodríguez-Morató, J., Pozo, Ó.J. and Marcos, J. (2018) Targeting Human Urinary Metabolome by LC-MS/MS: A Review. Bioanalysis, 10, 489-516. [Google Scholar] [CrossRef] [PubMed]
[35] Peitzsch, M., Mangelis, A., Eisenhofer, G., et al. (2019) Age-Specific Pediatric Reference Intervals for Plasma Free Normetanephrine, Metanephrine, 3-Methoxytyramine and 3-O-Methyldopa: Particular Importance for Early Infancy. Clinica Chimica Acta, 494, 100-105. [Google Scholar] [CrossRef] [PubMed]